'OLAP' (OLAparib Regulatory Post-marketing Surveillance)
NCT04553926 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 661
Last updated 2025-08-14
Summary
The objectives of this study are to assess safety and effectiveness of Lynparza tablet (olaparib, hereinafter "the study drug") in a real world setting in patients who are prescribed with the study drug according to the approved indications in South Korea
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Max Age
- 150 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-02-01
- Primary Completion
- 2025-07-11
- Completion
- 2025-07-11
Countries
- South Korea
Study Locations
More Related Trials
-
Olaparib In Metastatic Breast Cancer
NCT03344965 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
NCT05522491 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer
NCT03931551 ·Status: TERMINATED ·Phase: PHASE2
-
Short-term Presurgical Study to Assess Molecular Predictors of Lapatinib's Effects in Primary Breast Cancer
NCT00299286 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
NCT02681562 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
NCT02561832 ·Status: TERMINATED ·Phase: PHASE1
-
Testing Olaparib Either Alone or in Combination With Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer
NCT02849496 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency (COMPRENDO
NCT05033756 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer
NCT03150576 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
NCT02000622 ·Status: COMPLETED ·Phase: PHASE3
-
Lapatinib in Combination With Oral Vinorelbine for Metastatic Breast Cancer
NCT00912275 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer
NCT03544125 ·Status: COMPLETED ·Phase: PHASE1
-
Study Of Lapatinib In Patients With Relapsed Or Refractory Inflammatory Breast Cancer
NCT00105950 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Metastatic Breast Cancer
NCT01985893 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients
NCT01161368 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature
NCT02505048 ·Status: COMPLETED ·Phase: PHASE2
-
Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC
NCT03838367 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Analysis of Olaparib Response in Patients With BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer
NCT03205761 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK-7339-009/KEYLYNK-009)
NCT04191135 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
NCT04596150 ·Status: COMPLETED ·Phase: PHASE2
-
Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors
NCT01218529 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
NCT05967286 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of Palbociclib With Exemestane Plus GnRH Versus Capecitabine in Premenopausal Women With HR+ MBC
NCT02592746 ·Status: UNKNOWN ·Phase: PHASE2
-
A Phase 1b/2 Trial Evaluating Safety and Efficacy of CAPecitabine in Combination With Ni-rapaRIb in HER2-negative Advanced Breast canCEr
NCT05519670 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Lapatinib in Treating Patients With Advanced or Metastatic Breast Cancer That Overexpresses HER2
NCT00544804 ·Status: COMPLETED ·Phase: PHASE1